XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents.

Our business model is open and flexible, going from fee-for-service contracts to research collaborations with private pharmaceutical and biotech companies and academic laboratories. The company also conducts internal R&D programs focusing on the development of new models and technologies and the discovery of drug response markers (theranostics) and of novel therapeutic targets.